Question 1

Am I eligible for this trial based on my current health and treatment history?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) clinical trial (NCT00313781). Contact the study team or your healthcare provider for specific answers.

Question 2

How does CP-751,871 compare to other treatments I might consider?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) clinical trial (NCT00313781). Contact the study team or your healthcare provider for specific answers.

Question 3

What side effects should I expect from this combination treatment?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) clinical trial (NCT00313781). Contact the study team or your healthcare provider for specific answers.

Question 4

How often will I need to come in for treatment and monitoring?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) clinical trial (NCT00313781). Contact the study team or your healthcare provider for specific answers.

Question 5

What should I do if I experience side effects during the trial?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) clinical trial (NCT00313781). Contact the study team or your healthcare provider for specific answers.

Question 6

How will this trial impact my overall cancer treatment plan?

Accepted Answer

This is a question you may want to discuss with your doctor regarding the Study of CP-751,871 in Combination With Docetaxel and Prednisone in Patients With Hormone Insensitive Prostate Cancer (HRPC) clinical trial (NCT00313781). Contact the study team or your healthcare provider for specific answers.

What this study is about